Akebia Therapeutics, Inc. (AKBA) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Akebia Therapeutics is a commercial-stage biopharmaceutical company focused on kidney disease. Its portfolio includes Auryxia (ferric citrate), approved in the U.S. for hyperphosphatemia and iron deficiency anemia, and Vafseo (vadadustat), approved in the U.S. in March 2024 for anemia due to chronic kidney disease (CKD) in dialysis patients. Vafseo is expected to launch commercially in the U.S. in January 2025.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $37.4 million | $42.0 million | $113.7 million | $138.4 million |
| Net Loss | $(20.0) million | $(14.5) million | $(46.6) million | $(52.5) million |
| Net Loss Per Share | $(0.10) | $(0.08) | $(0.22) | $(0.28) |
| Cash & Equivalents | $34.0 million | $42.9 million | As of Sept 30, 2024 | |
| Operating Cash Flow (9M) | $(36.2) million | $(21.1) million | Used in operations | |
| Long-Term Debt (Net) | $38.4 million | $17.2 million | Includes BlackRock facility |
Note: The filing text does not provide a specific gross margin percentage; however, Cost of Goods Sold (COGS) was $14.2 million for Q3 2024.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 11% year-over-year in Q3 2024. Product revenue from Auryxia dropped to $35.6 million (from $40.1 million) due to reduced volume, partially offset by price increases. License revenue decreased due to lower royalties from Japanese partners.
- Cost Reductions: Cost of product revenue decreased 43% year-over-year to $5.2 million, driven by a $3.7 million benefit from selling inventory previously written down as excess.
- R&D Efficiency: Research and Development expenses decreased 36% to $8.5 million, attributed to the completion of certain clinical trials and lower headcount costs.
- Debt Restructuring: The company entered a new $55 million credit facility with BlackRock in January 2024, repaying prior Pharmakon term loans. This resulted in higher interest expense ($6.7 million in Q3 2024 vs. $1.4 million in Q3 2023) and a new warrant liability.
- Settlement Liability: Following the termination of the Vifor License Agreement in July 2024, the company reclassified $43.3 million of prior consideration as a debt liability, resulting in significant non-cash interest expense ($4.4 million in Q3 2024).
Guidance, Outlook, and Risks
- Vafseo Launch: The company expects Vafseo product availability in the U.S. in January 2025. CMS has determined Vafseo is eligible for Transitional Drug Add-on Payment Adjustment (TDAPA) reimbursement starting January 1, 2025.
- Auryxia Exclusivity: Auryxia will lose exclusivity in the U.S. in March 2025. The company anticipates potential revenue impacts from generic competition and the inclusion of phosphate binders in the ESRD bundled payment starting January 2025.
- Liquidity: Management believes current cash resources ($34.0 million) and expected revenues are sufficient to fund operations for at least 24 months. However, the company anticipates continued net losses.
- Material Weakness: The company identified a material weakness in internal controls over financial reporting related to inventory accounting as of December 31, 2023, which remains unremediated as of September 30, 2024.
- Key Risks: Risks include the ability to contract with dialysis organizations for Vafseo, potential delisting from Nasdaq if stock price remains below $1.00, and reliance on third-party manufacturers in China for Vafseo supply.
Investor Verification Checklist
- Inventory Accounting: Verify the remediation status of the material weakness regarding inventory reconciliations and costing, given the significant inventory write-downs and subsequent sales benefits recorded.
- Debt Covenants: Confirm compliance with BlackRock Credit Agreement covenants, specifically the requirement to maintain either $15 million in cash or $150 million in trailing twelve-month revenue.
- Vafseo Commercialization: Monitor progress on contracting with major dialysis organizations (e.g., DaVita, Fresenius) to ensure the January 2025 launch timeline is met.
- Auryxia Post-LoE Strategy: Assess the company's strategy to maintain Auryxia sales post-March 2025 exclusivity loss, particularly regarding the ESRD bundle payment changes.
- Settlement Royalties: Review the assumptions used to calculate the $47.7 million liability related to settlement royalties with CSL Vifor, as changes in sales estimates will impact interest expense.